Evidence map›Paper›PMID 37575091›Full record

ArticleMolecular therapy. Methods & clinical development2023

Efficient manufacturing and engraftment of

Jason Murray, Teresa Einhaus, Rasika Venkataraman, Stefan Radtke, Anjie Zhen, Mayra A Carrillo, Scott G Kitchen, Christopher W Peterson, Hans-Peter Kiem

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Molecular therapy. Advances · 2026
    Article
  2. Article
  3. Engraftment and persistence ofScience translational medicine · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jason MurrayStem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Teresa EinhausStem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Rasika VenkataramanStem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Stefan RadtkeStem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Anjie ZhenDepartment of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.
Mayra A CarrilloDepartment of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.
Scott G KitchenDepartment of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.
Christopher W PetersonStem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Hans-Peter KiemStem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Fred Hutch Cancer Center · USUniversity of California, Los Angeles · USUniversity of Washington · US

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
WaNPRC Macaca nemestrina SPF Breeding ColonyU42OD011123 · OD · UNIVERSITY OF WASHINGTON · PI Richard Grant · 2012 to 2026
$34.4M
Primate CoreU19HL156247 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CANNON, PAULA M, KIEM, HANS-PETER · 2020 to 2024
$14.6M
Viral Immunology CoreU19AI149504 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHEN, IRVIN S.Y., KITCHEN, SCOTT G · 2020 to 2024
$14.3M
Targeting a Novel Hematopoietic Stem Cell Population in Non-Human Primates for Effective and Sustained Gene TherapyR01AI135953 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KIEM, HANS-PETER · 2018 to 2022
$4.5M
In Vivo Gene Editing of B cells with NICE-AAV VectorsR01AI167004 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Christopher W Peterson · 2022 to 2026
$3.7M
Developing Durable, Env-Boosted CAR T Cells for HIV CureR01AI170214 · NIAID · FRED HUTCHINSON CANCER CENTER · PI Christopher W Peterson · 2023 to 2026
$3.4M
NHLBI NIH HHS U19 HL156247NIAID NIH HHS R01 AI135953NIAID NIH HHS R01 AI167004NIAID NIH HHS R01 AI170214NIAID NIH HHS U19 AI149504NIH HHS P51 OD010425NIH HHS U42 OD011123
6 · The paper itself

Abstract

Hematopoietic stem cell gene therapy has been successfully used for a number of genetic diseases and is also being explored for HIV. However, toxicity of the conditioning regimens has been a major concern. Here we compared current conditioning approaches in a clinically relevant nonhuman primate model. We first customized various aspects of the therapeutic approach, including mobilization and cell collection protocols, conditioning regimens that support engraftment with minimal collateral damage, and cell manufacturing and infusing schema that reflect and build on current clinical approaches. Through a series of iterative

Indexed as

autologous transplantcell therapyconditioningCRISPRgene therapyhematopoietic stem cellsnonhuman primate

Identifiers

PMID37575091
PMCPMC10415663
OpenAlexW4384699717

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.